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Background
A broad variety of systemic treatment options are avail-
able for non-resectable colorectal cancer in UICC stage
IV disease. Depending on age, comorbidity, the possibi-
lity of a secondary resection, the personal experience
with specific drug combinations, and national guidelines
physicians choose a treatment option. At present, only
Ki-ras status is determined as an individual biological
marker for resistance to anti-EGF receptor treatment
with cetuximab. The use of other molecular markers
could so far not be transferred to routine clinical use as
a guide for treatment of advanced colorectal cancer.
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synthesis and one major target of 5-fluorouracil (5-FU)
treatment. Several studies demonstrated that tumors
with high TS expression did not respond to 5-FU treat-
ment, whereas tumors with high TS may still respond to
irinotecan (CPT-11), a topoisomerase II inhibitor.
Aim
The aim of our study was to determine the value of pre-
therapeutic tumoral TS level for selecting chemotherapy.
Methods
We designed a phase II multicenter trial comparing
first-line monotreatment with 5-FU/folinic acid (FA)
and the combination of 5-FU/FA and irinotecan. A
biopsy from a reference lesion of patients with stage IV
non-resectable colorectal cancer planned to undergo
systemic palliative chemotherapy was taken. Relative TS
mRNA expression from microdissected tumor tissue
was determined followed by stratification in TS low and
TS high and subsequent randomisation to mono- or
combination treatment. Primary endpoint was response
to treatment.
Results
A total of 168 patients underwent TS determination. ITT
analysis of response revealed that toxicity was higher in
patients receiving combination treatment. Overall survival
not influenced by TS or treatment. Response to the com-
bination treatment was similar in the TS low and high
group. In contrast, response to 5-FU monotherapy was
higher in the TS low group in comparison to the TS high
group.
Conclusions
Individual determination of intratumoral TS is save and
feasible and can help to individualize systemic treatment
of advanced colorectal cancer. 5-FU monotherapy may
be an effective treatment option in patients with low TS
levels.
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